A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Joachim von Pawel,Silvia Novello,Rodryg Ramlau,Adolfo Favaretto,Fabrice Barlesi,Wallace Akerley,Sergey Orlov,Armando Santoro,David R. Spigel,Vera Hirsh,Frances A. Shepherd,Lecia V. Sequist,Alan Sandler,Jeffrey S. Ross,Qiang Wang,Reinhard von Roemeling,Dale Shuster,Brian Schwartz +18 more
TL;DR: E + T was well tolerated and increased PFS but did not improve OS in the overall nonsquamous NSCLC population, and exploratory subgroup analyses suggested OS improvement in patients with high MET expression.
Journal ArticleDOI
Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.
TL;DR: ABVD is an effective salvage regimen for MOPP-resistant Hodgkin's disease and 38% of patients who attained complete remission have remained alive and continuously disease free at 5 years from start of ABVD treatment.
Journal ArticleDOI
Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Vivien H.C. Bramwell,Jacques Rouëssé,William P. Steward,Armando Santoro,H Schraffordt-Koops,J. Buesa,W. Ruka,J Priario,T. Wagener,M Burgers +9 more
TL;DR: Adjuvant chemotherapy with CYVADIC cannot be recommended outside the context of a clinical trial, and experience from this study has been used to plan a trial of neoadjuant chemotherapy with doxorubicin/ifosfamide, which is currently in progress.
Journal ArticleDOI
Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas
Vivien H.C. Bramwell,Henning T. Mouridsen,Armando Santoro,G. R. P. Blackledge,Riet Somers,J. Verwey,P. Dombernowsky,M. Onsrud,D. Thomas,Richard Sylvester,A. van Oosterom +10 more
TL;DR: A higher response rate with less myelosuppression suggests that IFOS may have advantages over CYCLO in combination therapy, and serious infections occurred in approx.
Journal ArticleDOI
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Bonne Biesma,David F. Heigener,Joachim von Pawel,Timothy Eisen,Jaafar Bennouna,Li Zhang,Meilin Liao,Yan Sun,Steven Gans,Kostas N. Syrigos,Etienne Le Marie,Maya Gottfried,Johan Vansteenkiste,Vincente Alberola,Uwe Phillip Strauss,Elaine Montegriffo,Teng Jin Ong,Armando Santoro +18 more
TL;DR: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC.